A Randomized, Open-label, 2-period, 2-sequence Cross-over Trial to Compare the Pharmacokinetics of Tralokinumab of Two Presentations in Healthy Subjects
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Tralokinumab (Primary)
- Indications Alopecia areata; Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors LEO Pharma
- 04 Jan 2022 Status changed from active, no longer recruiting to completed.
- 18 May 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 22 Dec 2020 New trial record